Denali Therapeutics Balance Sheet
NASDAQ: DNLIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Denali Therapeutics financial position
At the end of fiscal 2025, Denali Therapeutics reported total assets of $1.14 billion, down 16.7% from a year earlier against total liabilities of $131.1 million. Shareholders' equity stood at $1.01 billion, or 88.5% of assets. The company held $205.3 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 9.16, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Denali Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 205.33M | 174.96M | 127.11M | 218.04M | 293.48M | 507.14M | 79.45M | 77.12M | 218.38M | 39.85M |
| Short-Term Investments | 662.55M | 657.37M | 907.40M | 1.12B | 571.93M | 962.55M | 335.91M | 387.17M | 187.85M | — |
| Receivables | 0 | — | — | — | — | 8.59M | — | — | — | — |
| Inventory | 0 | — | — | — | — | — | — | — | — | — |
| Total Current Assets | 900.66M | 864.44M | 1.06B | 1.37B | 897.23M | 1.50B | 430.03M | 480.84M | 409.61M | — |
| Property, Plant & Equipment | 52.40M | 55.24M | 45.59M | 44.09M | 38.87M | 40.85M | 46.73M | 25.16M | 14.92M | — |
| Intangible Assets | 0 | — | — | — | — | — | — | — | — | — |
| Long-Term Investments | 98.32M | 359.37M | 0 | 0 | 425.45M | 32.70M | 39.89M | 147.88M | 60.75M | — |
| Total Assets | 1.14B | 1.37B | 1.15B | 1.46B | 1.40B | 1.60B | 553.23M | 661.98M | 486.72M | — |
| Accounts Payable | 505.00K | 11.14M | 9.48M | 2.79M | 4.78M | 1.07M | 2.59M | 1.89M | 2.72M | — |
| Total Current Liabilities | 98.35M | 102.21M | 77.98M | 363.92M | 378.25M | 71.70M | 45.34M | 32.79M | 14.16M | — |
| Total Liabilities | 131.09M | 144.50M | 122.96M | 417.81M | 441.87M | 453.75M | 158.34M | 115.14M | 20.93M | — |
| Shareholders' Equity | 1.01B | 1.23B | 1.03B | 1.04B | 962.29M | 1.15B | 394.89M | 546.85M | 465.80M | -94.15M |
| Retained Earnings | -2.05B | -1.54B | -1.12B | -970.99M | -645.00M | -354.42M | -425.55M | -227.94M | -191.70M | — |
| Net Cash (Debt) | 867.88M | 832.33M | 1.03B | 1.34B | 865.41M | 1.47B | 415.36M | 464.30M | 406.23M | 39.85M |
| Shares Outstanding | 156.18M | 144.22M | 138.39M | 135.97M | 122.28M | 120.53M | 96.19M | 94.66M | 87.48M | — |
This table shows 10 annual periods of Denali Therapeutics's balance sheet, from FY 2025 back to FY 2016, across 16 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow DNLI's reporting calendar. What is a balance sheet?